#Breaking from #ESMO25: We’re presenting new data across our #oncology portfolio, reinforcing our commitment to transformative innovation in some of the most challenging cancers, including breast, bladder, lung and gastrointestinal. Learn more: https://t.co/C6MTLOE04h

Breaking: The @US_FDA approved our new treatment regimen for extensive-stage small cell lung cancer (ES-SCLC), where maintenance therapy may help combat the risk of progression. Learn more: https://t.co/zZbG5BqZZe

#Breaking: At #ECTRIMS2025, we’re presenting new data from our multiple sclerosis portfolio across broad populations, including individuals living with RRMS and PPMS. Read the press release here:

#Breaking: New Phase III data shows a meaningful advancement for people with ER+, HER2- advanced #BreastCancer. Read the release: https://t.co/gXyuCs2hZS

#Breaking: We presented late-breaking four-year data of our bispecific antibody in people with wet AMD and Phase IIIb/IV data in PCV, a subtype of this severe eye condition, at #EURETINA2025 ➡Read the full details here: https://t.co/qjcHO1FH4i

#Breaking: Today we announced the decision to initiate a Phase III trial evaluating our investigational RNAi therapy for people with #hypertension, which is informed by Phase II data we presented at #ESC2025. Discover how we are committed to advancing cardiovascular care:

Today we broke ground on our new $700M facility in Holly Springs, NC—Genentech’s first East Coast site. This 700K-sq-ft hub will support next-gen metabolic medicines and create 1,900+ jobs, strengthening U.S. innovation in biotech. https://t.co/3sP0EHBJPD

#Breaking: At #ASRS2025, we’re sharing results from our latest ophthalmology research, including data from our long-term, five-year study in people with wet age-related macular degeneration. Read the press release here: https://t.co/dLJoy7U5WU

#Breaking: At AAIC, we’re presenting new data in #Alzheimers, underscoring our commitment to advancing the science in this disease. Learn More: https://t.co/H05zAiidbF

#Breaking: At #18ICML, we’re presenting data from our Phase III trial revealing how our novel combination therapy helped reduce the risk of disease progression for people living with large B-cell #lymphoma (#LBCL) in an outpatient setting. Learn more: https://t.co/VP1qNR91Fr

#Breaking: Today we announced we will advance our investigational medicine in early #ParkinsonsDisease into Phase III development. Learn more: https://t.co/hu7rxwRYSb

#Breaking at #ASCO25: We will present Phase III data, also published in @TheLancet, for ES-SCLC, offering a potential option for this aggressive cancer. Learn more: https://t.co/ZRM2esPJGH

#Breaking: We’re presenting new survival data for PIK3CA-mutated HR+, HER2- advanced #breastcancer at #ASCO25, also published in #NEJM. Read about the results here: https://t.co/3Ss0XqYTsK

#Breaking: We’re excited to share two-year data from our investigational BTK inhibitor for people with relapsing multiple sclerosis (RMS) presented at this year’s #CMSC2025 meeting. Learn more about the results here:

At #ASCO25, we will present two-year follow-up data from our Phase III study that reinforces the potential of a CD20xCD3 bispecific antibody combined with chemotherapy in relapsed or refractory diffuse large B-cell #lymphoma. Learn more: https://t.co/zN0H87dVbk

#Breaking: The @US_FDA has approved our treatment in a new indication for #DiabeticRetinopathy (DR). Learn more about how this treatment offers a new alternative to the standard of care for people with DR: https://t.co/p4ghPj8u8y

#Breaking: This #ESMOBreast25, we are excited to present ten-year follow-up data reinforcing the potential benefit of our treatment for HER2-positive early-stage breast cancer. Learn more: https://t.co/PM85MFAuNF

#Breaking: @NEJM published a detailed analysis of positive Phase III data for our influenza treatment and household #influenza transmission. Learn more: https://t.co/sNZ2VdvNqQ #PublicHealth #Flu

#Breaking: We’re presenting new data at #ADPD2025 showcasing advancements in our #Alzheimers research for the millions of people living with Alzheimer’s disease. Learn more: https://t.co/yXXcy6z6Qx

ICYMI: Our supplemental Biologics License Application for our anti-CD20 monoclonal antibody for lupus nephritis treatment was accepted by the @US_FDA. Learn more: https://t.co/anqpIaZSwr